

Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura

X. Long Zheng¹   | Sara K. Vesely² | Spero R. Cataland³  | Paul Coppo⁴ | Brian Geldziler⁵ | Alfonso Iorio^{6,7}  | Masanori Matsumoto⁸ | Reem A. Mustafa⁹ | Menaka Pai⁷ | Gail Rock¹⁰ | Lene Russell¹¹  | Rawan Tarawneh¹² | Julie Valdes¹³ | Flora Peyvandi^{14,15}

¹Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA

²Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

³Department of Medicine, Ohio State University, Columbus, OH, USA

⁴Centre de Référence des Microangiopathies Thrombotiques, Service d'Hématologie, Hôpital Saint-Antoine, Sorbonne Université, Assistance Publique, Hôpitaux de Paris, Paris, France

⁵Somerset, NJ, USA

⁶Department of Health Research Methods, Research, and Impact, McMaster University, Hamilton, ON, Canada

⁷Department of Medicine, McMaster University, Hamilton, ON, Canada

⁸Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan

⁹Department of Medicine, The University of Kansas Medical Center, Kansas City, KS, USA

¹⁰University of Ottawa, Ottawa, ON, Canada

¹¹Department of Intensive Care, Copenhagen University Hospital, Copenhagen, Denmark

¹²Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA

¹³Morristown, NJ, USA

¹⁴Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

¹⁵Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

Correspondence

X. Long Zheng, Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, 3901 Rainbow Blvd, 5016 Delp, Kansas City, KS 66160, USA.

Email: xzheng2@kumc.edu or longzheng01@gmail.com

Funding information

Educational fund from International Society of Thrombosis and Haemostasis

1 | METHODS

Upon setting the Population, Intervention, Comparison, and Outcome questions for the guidelines, the panel identified a number of topics that might be well suited to non-Grading of Recommendations

Assessment, Development, and Evaluation Good Practice Statements (GPSs). The McMaster team drafted an initial set of statements for distribution to the panelists before our second in-person meeting. The panelists reviewed the statements for relevance and accuracy.

All authors except for the first, second, and last authors are listed in alphabetical order.

Manuscript handled by: Marcel Levi

Final decision: Marcel Levi, 10 July 2020

["Correction Statement added on October 18, 2020: an abstract was included by mistake and has since been removed."]

© 2020 International Society on Thrombosis and Haemostasis

The GPSs were then revised based on feedbacks that were redistributed to the panelists for further revisions and finalization.

2 | COMMENT

The Guidelines panel discussed a number of additional considerations to support good clinical care of patients with thrombotic thrombocytopenic purpura (TTP). The "GPSs" are not evidence-based recommendations. Specifically, they are not based on systematic search or formal review of the evidence. These statements are intended to provide a "snapshot" of the care provided to patients with TTP by expert health care providers. They address scenarios in which there is very limited high-certainty evidence, yet there is a body of indirect evidence and/or clinical experience that suggests the net benefit of certain actions. GPSs are intended to guide health care providers who have limited experience in treating TTP. They should be used with caution; the provider's own clinical judgment, in combination with the individual patient's clinical situation, values, and preferences, should all be considered.

3 | SUPPORTIVE CARE

The following statements pertain to initial emergency care and general supportive care of patients with TTP.

3.1 | Statement 1

Clinicians generally consider a diagnosis of TTP in individuals presenting with thrombocytopenia and microangiopathic hemolytic anemia.¹⁻⁴ Patients may be critically ill, or may have relatively minor and nonspecific complaints. Importantly, the classic signs of TTP (eg, hemolytic anemia, thrombocytopenia, fever, neurologic abnormalities, and renal abnormalities) also known as "Raynaud's Pentad" are present in only 40% of patients; therefore, the historical pentad only are only seen in the more severe forms of the disease, or in patients left without appropriate treatment resulting from a delayed diagnosis. The prevalence of this catastrophic presentation has decreased in past few decades as the result of better awareness of the disease among practitioners.⁴⁻⁷ Therefore, the presence of thrombocytopenia and microangiopathic hemolytic anemia without other explanation should prompt a suspicion of TTP in the differential diagnosis.⁸

3.2 | Statement 2

We did not systematically search and review the evidence on different clinical or laboratory approaches for diagnostic workup of a patient with suspected TTP. However, an initial laboratory evaluation of presumptive TTP should include a complete blood count with

careful review of a peripheral blood film for lack of platelets and presence of fragmented red blood cells (or schistocytes), serum lactate dehydrogenase, and creatinine, testing to demonstrate hemolysis (eg, low haptoglobin, increased indirect bilirubin), coagulation testing (which is expected to be relatively normal in TTP unless it is a severe form of the disease⁵ and there is a concomitant disseminated intravascular coagulation).⁹ A direct Coombs test is expected to be negative in TTP, but may be positive in autoimmune hemolytic anemia. Troponin I and electrocardiogram should be systematically performed to identify subclinical cardiac involvement.^{5,10,11} Computed tomography/magnetic resonance imaging of the brain may also be included in the initial evaluation for TTP if there are symptoms and signs, suggestive of brain injury.¹²⁻¹⁶

3.3 | Statement 3

If the index of suspicion for TTP is high, clinicians should consider the emergency initiation of therapeutic plasma exchange (TPE) and corticosteroids. Because of the severity and instability of their illness, and the foundational role of TPE in the treatment of TTP, patients experiencing an acute event of TTP are usually urgently transferred to a facility that can perform TPE, ideally overseen by a clinician who has expertise in the management of TTP. Most of these patients (>95%) if plasma ADAMTS13 activity is less than 10 IU/dL (or <10% of normal) are immune-mediated TTP or iTTP.

For a suspected iTTP, a blood sample should be obtained for plasma ADAMTS13 testing (eg, activity and inhibitors or anti-ADAMTS13 IgG, etc.) before the initiation of TPE. Daily TPE is generally initiated as soon as possible with fresh frozen plasma (FFP), or cryopoor plasma, or solvent detergent-treated (SD) plasma as a replacement fluid. The volume of the replacement fluid is usually 1.0 to 1.5 times of patient's plasma volume (ie, 40-60 mL/kg) every 24 hours until normalization of patient's platelet counts and serum lactate dehydrogenase.

Patients with a suspected or confirmed hereditary or congenital TTP (cTTP) are generally treated with plasma infusion (10 to 15 mL/kg) at a frequency of every 1 to 3 weeks for maintenance therapy or daily for a symptomatic patient until the symptoms resolve and normalization of platelet counts.¹⁷⁻¹⁹

3.4 | Statement 4

Because of the severity and instability of their illness, TTP patients experiencing an acute event are often managed in a setting with critical/intensive care capabilities, including continuous monitoring of neurologic status, cardiac status, and oxygen saturation. Initial management in a critical/intensive care setting is considered appropriate on the grounds that TTP patients may deteriorate quickly, and have a high risk of severe organ dysfunction such as coma, ischemic stroke, seizures, myocardial infarction, congestive heart failure, arrhythmias, mesenteric ischemia, pancreatitis, and acute kidney injury. All

of these complications require early detection, intensive care monitoring, and rapid therapeutic interventions; furthermore, TPE is associated with rare adverse effects, such as anaphylactic reactions, that are best managed in the critical/intensive care setting.^{20,21}

3.5 | Statement 5

We did not systematically search and review the evidence on different modalities of monitoring in TTP patients. In general, the clinical evaluation of TTP patients at the time of hospital admission, and regularly thereafter, emphasizes cardiac and neurological assessment. Specifically, cardiac troponin levels are measured at diagnosis, followed by serial troponin levels, electrocardiography, and echocardiography as clinically indicated.²² Increased cardiac troponin ($>0.25 \mu\text{g/L}$) appears to be associated with increased cardiac and cerebral involvement, ischemic stroke, and mortality in TTP,⁵ although most patients with an increased level of cardiac troponin remain asymptomatic.^{5,10,23,24}

3.6 | Statement 6

TTP patients often need a central venous access secured urgently. Rapid placement of central venous access allows TPE to be initiated as soon as possible. The type of central venous access depends on the modality of TPE: centrifugal apheresis vs membrane filtration. Centrifugal apheresis involves lower blood flow rates, and enables the use of catheters with smaller diameters, and more flexible walls (such as peripheral catheters or standard triple lumen central venous catheters). Conversely, membrane filtration involves higher blood flow rates, which requires the use of larger diameter, stiffer catheters (such as standard dialysis catheters or single lumen central venous catheters).²⁵⁻²⁹ Clinicians should be aware of, or consult the appropriate service for what modality of TPE is used at their center, so appropriate central venous access can be secured before initiation of TPE.

3.7 | Statement 7

The risk of catheter-related complications such as bleeding, thrombosis, and sepsis are increased in patients with TTP.³⁰ We did not systematically search and review the evidence on strategies to reduce the risk of bleeding around catheter placement. Depending on local practice and resource availability, procedures to minimize the risk of bleeding may be considered, including placement by an experienced clinician, ultrasound-guided placement, and internal jugular vein or femoral vein access (rather than subclavian vein access).³¹⁻³³ Once the platelet count increases and the patient is stable, clinicians usually regularly review whether lines need to be changed and whether venous thromboembolism prophylaxis should be considered.

3.8 | Statement 8

We did not systematically search and review the evidence on the beneficial or harmful effects of platelet transfusions in TTP. Platelet transfusions are usually avoided and considered unnecessary in most cases of TTP. However, platelet transfusion is often carried out before a correct diagnosis of TTP has been made. There are case reports in TTP patients of the association between platelet transfusions and arterial thrombosis, clinical deterioration, and increased relapse rate.³³⁻³⁵ However, the causative role of platelet transfusion is not clear. In general, prophylactic platelet transfusions are avoided in nonbleeding TTP patients because their effect is not clear and they carry the potential risk of adverse events, especially when transfusions are repeated. However, platelet transfusions are sometimes used in TTP patients with serious bleedings, or in TTP patients undergoing invasive procedures with a high risk of bleeding.³⁵ However, whether platelet transfusion should be performed before central line placement depends on the experience of the individual placing the line and the patient's overall bleeding risk.

3.9 | Statement 9

Based on indirect evidence in other critically ill patients, patients with TTP usually receive venous thromboembolism (VTE) prophylaxis. Nonpharmacologic VTE prophylaxis (ie, ambulation as tolerated, graduated compression stockings, intermittent pneumatic compression devices) is usually used while the platelet count is $<50 \times 10^9/\text{L}$. Once the platelet count is $>50 \times 10^9/\text{L}$, pharmacologic VTE prophylaxis such as low molecular weight heparin should be considered.

3.10 | Statement 10

We did not systematically search and review the evidence on long-term complications of TTP. In patients that have recovered from an acute TTP episode, the panel acknowledged the importance of monitoring for the development of mood disorders, neurocognitive symptoms (including short-term memory issues), and hypertension, which may develop during remission. Specific recommendations regarding screening for long-term complications cannot be made at this time, but serial follow-up and monitoring for these complications should be considered part of routine follow-up.

3.11 | Statement 11

We did not systematically search and review the evidence on the role of support groups for TTP patients. Health care providers may consider offering patients with TTP professional online resources and/or support groups for this rare disease. A number of established support groups exist for individuals with TTP who are going through or have gone through similar experiences. These are listed in Table 1.

4 | RELAPSE PREVENTION

In this section, the panel provides statements pertaining to the relapse prevention beyond what has provided in Recommendations 3-5.

4.1 | Statement 12

We did not systematically review the evidence on triggers for relapse. However, a number of potential triggers for relapse have been suggested in patients with TTP who have achieved clinical remission.^{17,36,37} Any illness or a special health condition can trigger a relapse; however, the most commonly discussed triggers include:

- Infections, including influenza, community-acquired pneumonia, periodontal and dental infections, and gastroenteritis
- Pregnancy
- Major trauma or surgery
- Intake of oral contraceptives
- Cocaine and other recreational drugs
- Intake of other drugs including quinine, ticlopidine, clopidogrel, check point inhibitors, cyclosporine, and tacrolimus, etc.
- Pancreatitis

Clinicians usually counsel patients on triggers for relapse and encourage them to seek medical attention for concerning signs and symptoms of any illness.

4.2 | Statement 13

We did not systematically search and review the evidence on the role of ADAMTS13 monitoring in TTP patients in remission. Patients in remission are usually assessed regularly during follow-up (typically every month for the first 3 months, then every 3 months for the first year, then every 6-12 months if stable). If available, ADAMTS13 activity is usually measured serially during

each follow-up assessment, and more frequently if levels begin to drop. Durably stable ADAMTS13 activity close to the lower limit of normal is usually a reassuring finding. Conversely, patients with persistently low ADAMTS13 activity (<10 IU/dL or 10% of normal) may be at risk for relapse, which may be prevented by administration of rituximab.^{38,39}

5 | OTHER TREATMENT AGENTS FOR TTP

The following nine statements pertain to the use of TTP treatment strategies that fall outside of the panel's prespecified Population, Intervention, Comparison, Outcome questions.

5.1 | Statement 14

We did not systematically search and review the evidence on vincristine for TTP patients. Patients with refractory TTP unresponsive to standard treatments may be considered for other immunosuppressive treatments (with scant supporting evidence), such as vincristine.⁴⁰⁻⁴³ In these cases, vincristine (2 mg) is usually administered intravenously, at a slow rate of infusion. Typically, a single dose is used because additional doses can cause neurotoxicity and bone marrow suppression.⁴⁴

5.2 | Statement 15

We did not systematically search and review the evidence on cyclosporine A for TTP patients. Patients with refractory TTP unresponsive to standard treatments may be considered for other immunosuppressive treatments (with scant supporting evidence), such as cyclosporine A. In these cases, cyclosporine A is usually administered orally (300 mg/day) or intravenously (2-3 mg/kg/day, divided twice daily). The appropriate duration of therapy is unknown, although administration of this drug for several months, followed by tapering, has been reported.⁴⁵⁻⁵¹

Group name	Region/Country	Website
Answering TTP	Canada	https://www.answeringtpp.org/
Association ADAMTS13	France	https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=FR&Expert=96406
Associazione Nazionale Porpora Trombotica Trombocitopenica (ANPTT)	Italy	http://www.anptt.org/
Japanese group for cTTP patients	Japan	https://www.facebook.com/uss.ttp/
Oklahoma TTP-HUS Support Group Meetings	Oklahoma, USA	https://ouhsc.edu/platelets/TTP/pt%20group%20meetings.html
The Rhee Wynn Foundation	New Jersey, USA	https://www.reewynn.org/

TABLE 1 A list of TTP professional online resources and/or support group

5.3 | Statement 16

We did not systematically search and review the evidence on cyclophosphamide for TTP patients. Patients with refractory TTP unresponsive to standard treatments may be considered for other immunosuppressive treatments (with scant supporting evidence), such as cyclophosphamide. In these cases, cyclophosphamide (500 mg/day) is usually administered intravenously over a 2-hour period. Typically, a single dose is used because additional doses may cause severe bone marrow suppression.^{8,44,51-53}

5.4 | Statement 17

We did not systematically search and review the evidence on splenectomy for TTP patients. This procedure has been largely superseded by other treatments such as rituximab. It is generally not used, but may still have a role in selected TTP patients as a prophylactic/treatment strategy.⁵⁴⁻⁵⁸

5.5 | Statement 18

We did not systematically search and review the evidence on azathioprine for TTP patients. Clinicians sometimes may consider azathioprine to inhibit anti-ADAMTS13 autoantibody production, which leads to normalization of plasma ADAMTS13 activity and prevents relapse in patients with refractory disease unresponsive to standard treatments.⁵⁹

5.6 | Statement 19

We did not systematically search and review the evidence on antiplatelet agents for TTP patients. Antiplatelet agents have been used in nonpregnant patients with TTP,⁶⁰⁻⁶⁵ particularly in the setting of macrothrombotic complications (eg, ischemic stroke and myocardial infarction). Otherwise, antiplatelets are not generally recommended in TTP; their role in preventing relapse is not supported in the literature, and they may be harmful in the acute phase of TTP when the platelet count is low (eg, $<50 \times 10^9/L$). Inputs from cardiologists, neurologists, and/or other vascular medicine specialists are usually sought if antiplatelet agents are considered in the treatment of TTP-related complications.

5.7 | Statement 20

We did not systematically search and review the evidence on anti-C5 monoclonal antibody (eg, eculizumab) for TTP patients. Increased complement activation has been demonstrated in patients with acute TTP. Therefore, clinicians sometimes consider eculizumab in very selected patients with refractory disease or those unresponsive

to all other treatment options.^{66,67} This strategy should be pursued with caution.

5.8 | Statement 21

We did not systematically search and review the evidence on intravenous immunoglobulin (IVIG) for TTP patients. IVIG is generally not used in TTP. Its efficacy is unknown, and adverse reactions to this product mimic thrombotic, neurologic, and renal manifestations of TTP.^{68,69}

5.9 | Statement 22

We did not systematically search and review the evidence on corticosteroid dosage, dose adjustment, or tapering in TTP. In patients with TTP, high dose corticosteroids (eg, prednisone, 1 mg/kg per day, orally, or methylprednisolone, 125 mg, IV, two to four times daily) are usually used as the initial regimen.^{3,4,45,70} If the platelet count does not increase within 3 to 4 days of treatment, a higher dose of corticosteroids is usually used. High doses of corticosteroids are usually continued until the platelet count is recovered and TPE is stopped. When platelet count recovery is sustained (eg, after 5-7 days), corticosteroids are usually tapered and discontinued over a 3-week period. Tapering may be delayed or slowed based on platelet count, ADAMTS13 test results, and/or neurological symptoms.^{44,70}

6 | TTP AND WOMEN'S HEALTH

The following statements pertain to women's health issues in patients with history of TTP: perinatal care; contraception; and pregnancy counseling.

6.1 | Statement 23

Women with a history of TTP who are planning for pregnancy usually receive preconception counseling. The panel acknowledged the importance of offering counseling to all women with a history of TTP who are considering for pregnancy. The risks of TTP with a somewhat unpredictable course must be discussed during the counseling. The patient's individual values and preferences must also be considered. Pregnancy can trigger TTP relapse, resulting in an increased risk of maternal and fetal mortality and morbidity. It is difficult to predict who may experience a relapse during pregnancy. A normal plasma ADAMTS13 activity at the onset of pregnancy in patients with a history of TTP may be associated with a reduced risk of immediate relapse, while a low (eg, $<10 IU/dL$) plasma ADAMTS13 activity at the onset of pregnancy may be associated with an increased risk of relapse.⁷¹

6.2 | Statement 24

In some institutions, women with a decreased ADAMTS13 activity (eg, <10 IU/dL) before or at the onset of pregnancy are offered an prophylactic rituximab therapy, with a goal to eliminate anti-ADAMTS13 autoantibodies and normalize plasma ADAMTS13 activity before conception. Evidence of normal ADAMTS13 activity may be associated with a lower risk of relapse in women with a history of TTP.^{71,72}

6.3 | Statement 25

Patients treated with rituximab are usually asked to wait for 6 to 12 months following rituximab administration before trying to conceive; normalization of CD19 lymphocyte levels and undetectable serum rituximab levels are often used as the evidence of "drug washout."^{19,73} Global drug safety databases suggest that rituximab is associated with few congenital malformations or neonatal infections. However, scant case reports of its use in patients with TTP did not report maternal or neonatal toxicity.^{74,75} Nevertheless, women should be informed that the evidence about the safety and efficacy of rituximab in pregnancy is extremely limited and inconclusive.

6.4 | Statement 26

Pregnant women with a history of TTP are usually closely monitored by a hematologist and an obstetrician with experience in maternal fetal medicine/perinatology. The panel supports the involvement of clinicians with expertise in TTP in the care of pregnant women with a history of TTP. Complete blood counts are usually monitored at least monthly. Plasma ADAMTS13 activity is usually monitored monthly or every 2 to 3 months at least. (More frequent monitoring tends to occur if the ADAMTS13 activity begins to drop during pregnancy).

6.5 | Statement 27

TTP presenting in pregnancy generally merits a transfer to a more specialized center with hematologist, obstetrician, and transfusion medicine specialists, and TPE capabilities, for comprehensive and definitive care. As in the case of TTP in nonpregnant patients, daily TPE is generally needed as soon as possible with FFP, or cryopoor plasma, or SD plasma as a replacement fluid. The volume of replacement fluid is usually 1.0 to 1.5 times of patient's plasma volume (ie, 40-60 mL/kg) every 24 hours.^{74,76}

6.6 | Statement 28

Women with a history of TTP require close monitoring by a hematologist with experience in TTP and maternal fetal medicine throughout

pregnancy. Their risk of relapse is generally considered to be high if they enter pregnancy with plasma ADAMTS13 activity below the normal range. If plasma ADAMTS13 activity falls significantly (eg, usually <30 IU/dL or 30% of normal) even in the absence of clinical signs/symptoms, TPE and corticosteroids (or azathioprine) are often considered.

It is a good practice to monitor ADAMTS13 activity throughout pregnancy and during the postpartum period. Induction of labor at 36 to 37 weeks' gestation is commonly suggested.^{77,78} In the absence of other obstetrical indications for cesarean section, vaginal delivery is considered a preferred method of delivery in pregnant women with a history of TTP. This statement also applies to women with a history of either cTTP or iTTP.

6.7 | Statement 29

Women with a history of TTP who are planning pregnancy usually receive preconception counseling. Pregnant women with a history of TTP have a high risk of serious complications during pregnancy.⁷⁸ They receive plasma infusion, at a dose of 10 to 15 mL/kg weekly or every 2 weeks, or TPE, depending on the symptoms. Beginning in the second or early third trimester, the frequency of infusion is usually increased to weekly or twice weekly or TPE. Women with a history of TTP require close monitoring by a hematologist with experience in maternal fetal medicine throughout pregnancy. Induction of labor at 36 to 37 weeks' gestation is commonly suggested.⁷⁷ In the absence of other obstetrical indications for cesarean section, vaginal delivery is considered the preferred method of delivery in pregnant women with a history of TTP. These statements apply to women with a history of either cTTP or iTTP.

6.8 | Statement 30

We did not systematically search and review the evidence on the effect of aspirin in pregnant women with TTP. Largely based on indirect evidence from other populations, pregnant women with a history of TTP are usually not offered low-dose aspirin throughout pregnancy.¹⁹

6.9 | Statement 31

We did not systematically search and review the evidence on the effect of antithrombotic therapy in pregnant women with TTP. Largely based on indirect evidence from other populations, pregnant women with a history of TTP, and a history of venous thrombosis, are usually offered low molecular weight heparin at prophylactic doses throughout pregnancy, with the goal of preventing the formation of placental microthrombi and insufficiency, as well as preventing recurrent venous thrombosis.¹⁹ Offering antithrombotic therapy to women with a history of TTP-associated pregnancy loss, but not venous thrombosis, remains controversial.

6.10 | Statement 32

We did not systematically search and review the evidence on the effect of hormonal preparations, particularly those containing estrogen, as a potential trigger for relapse in women with TTP. Women with a history of TTP are usually counseled that nonhormonal methods of contraception and progestin-only preparations are preferred over estrogen-containing preparations that may promote production of autoantibodies against ADAMTS13.⁷⁹⁻⁸⁴

7 | REFUSAL OF BLOOD PRODUCTS

The following statement pertains to care of TTP in patients who refuse blood products.

7.1 | Statement 32

We did not systematically search and review the evidence on alternatives to blood products in TTP patients. Patients with TTP refusing blood products (eg, Jehovah's Witnesses) generally will not accept TPE with replacement of plasma. Clinicians should explore patients' values and preferences to determine if they will accept albumin and other purified protein fractions because these products are sometimes acceptable. This strategy can, at minimum, help remove ADAMTS13 autoantibodies and other potential harmful inflammatory mediators. Clinicians may empirically consider the use of corticosteroids, rituximab, and caplacizumab as well as erythropoietin and folic acid (to promote erythropoiesis).⁸⁵⁻⁹² If the patient will accept plasma derivatives, factor VIII concentrates containing sufficient amounts of ADAMTS13 may be considered instead of plasma.^{90,91} If the patient will accept albumin, TPE with albumin as the replacement fluid may be considered.^{88,90}

ACKNOWLEDGMENTS

This work is supported by ISTH educational fund.

CONFLICT OF INTEREST

Dr. Zheng is a speaker and consultant for Alexion, Sanofi-Genzyme, and Takeda, as well as the cofounder of Clotsolution; Dr. Vesely is a biostatistician for the Oklahoma TTP registry; Dr. Cataland is a consultant for Sanofi-Genzyme and Takeda and served on an advisory board for Alexion; Dr. Coppo is a consultant for Sanofi-Genzyme, Alexion, and Takeda; Dr. Matsumoto has received royalty interest from Alfrexa Pharma; Dr. Peyvandi is a speaker for Spark Therapeutics, Sobi, Bioverativ, Grifols, Takeda, and Sanofi-Genzyme; Dr. Geldziler is an employee of Merck Pharmaceuticals. Dr. Iorio declare no conflict of interest, but reports that his institution has received project-based funding via research or service agreements from Bayer, CSL, Grifols, NovoNordisk, Octapharma, Pfizer, Roche, Sanofi, Sobi, Spark, and Takeda; Dr. Pai and other authors whose

names are not specifically mentioned in this section declare no conflict of interest.

AUTHOR CONTRIBUTIONS

X. L. Zheng, Sara K. Vesely, Menaka Pai, and Flora Peyvandi reviewed the literature and wrote manuscript; all other authors revised and approved the final version of the manuscript.

ORCID

X. Long Zheng  <https://orcid.org/0000-0003-1680-5295>

Spero R. Cataland  <https://orcid.org/0000-0001-8977-6910>

Alfonso Iorio  <https://orcid.org/0000-0002-3331-8766>

Lene Russell  <https://orcid.org/0000-0001-7352-8728>

TWITTER

X. Long Zheng  @DrXLongZheng

REFERENCES

1. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. *N Engl J Med*. 1991;325:393-397.
2. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. *N Engl J Med*. 1991;325:398-403.
3. Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. *Blood*. 2004;103:4043-4049.
4. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. *Blood*. 2017;129:2836-2846.
5. Staley EM, Cao W, Pham HP, et al. Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura. *Haematologica*. 2019;104:166-175.
6. Moake JL. Thrombotic microangiopathies. *N Engl J Med*. 2002;347:589-600.
7. Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. *J Thromb Haemost*. 2017;15:312-322.
8. Saha M, McDaniel JK, Zheng XL. Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics. *J Thromb Haemost*. 2017;15:1889-1900.
9. Wang Z, Yu Z, Su J, Cao L, Zhao X, Ruan C. Sepsis-induced disseminated intravascular coagulation with features of thrombotic thrombocytopenic purpura: a fatal fulminant syndrome. *Clin Appl Thromb Hemost*. 2011;17:251-253.
10. Brazelton J, Oster RA, McCleskey B, Fuller J, Adamski J, Marques MB. Increased troponin I is associated with fatal outcome in acquired thrombotic thrombocytopenic purpura. *J Clin Apher*. 2017;32:311-318.
11. Hughes C, McEwan JR, Longair I, et al. Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. *J Thromb Haemost*. 2009;7:529-536.
12. Rinkel GJ, Wijdeveld EF, Hene RJ. Stroke in relapsing thrombotic thrombocytopenic purpura. *Stroke*. 1991;22:1087-1089.

13. Downes KA, Yomtovian R, Tsai HM, Silver B, Rutherford C, Sarode R. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. *J Clin Apher.* 2004;19:86-89.
14. Scheid R, Hegenbart U, Ballaschke O, Von Cramon DY. Major stroke in thrombotic-thrombocytopenic purpura (Moschowitz syndrome). *Cerebrovasc Dis.* 2004;18:83-85.
15. Boattini M, Procaccianti G. Stroke due to typical thrombotic thrombocytopenic purpura treated successfully with intravenous thrombolysis and therapeutic plasma exchange. *BMJ Case Rep.* 2013;2013:bcr2012008426.
16. Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. *J Thromb Haemost.* 2017;15:1448-1452.
17. Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. *Best Pract Res Clin Haematol.* 2001;14:437-454.
18. Kinoshita S, Yoshioka A, Park YD, et al. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. *Int J Hematol.* 2001;74:101-108.
19. Scully M, Thomas M, Underwood M, et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. *Blood.* 2014;124:211-219.
20. Mortzell M, Berlin G, Nilsson T, et al. Analyses of data of patients with thrombotic microangiopathy in the WAA registry. *Transfus Apher Sci.* 2011;45:125-131.
21. Shatzel JJ, Taylor JA. Syndromes of thrombotic microangiopathy. *Med Clin North Am.* 2017;101:395-415.
22. Zafrani L, Russell L, Azoulay E. Does this patient with thrombotic thrombocytopenic purpura have a cardiac involvement? *Intensive Care Med.* 2018;44:893-896.
23. Benhamou Y, Boelle PY, Baudin B, et al. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference. Center. *J Thromb Haemost.* 2015;13:293-302.
24. Gandhi K, Aronow WS, Desai H, et al. Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience. *Clin Cardiol.* 2010;33:213-216.
25. Spindler JS. Subclavian vein catheterization for apheresis access. *J Clin Apher.* 1983;1:202-205.
26. Haller W, Milford DV, Goodship TH, Sharif K, Mirza DF, McKiernan PJ. Successful isolated liver transplantation in a child with atypical hemolytic uremic syndrome and a mutation in complement factor H. *Am J Transplant.* 2010;10:2142-2147.
27. Kalantari K. The choice of vascular access for therapeutic apheresis. *J Clin Apher.* 2012;27:153-159.
28. Golestaneh L, Mokrzycki MH. Vascular access in therapeutic apheresis: update 2013. *J Clin Apher.* 2013;28:64-72.
29. Tanhehco YC, Zantek ND, Alsammak M, et al. Vascular access practices for therapeutic apheresis: results of a survey. *J Clin Apher.* 2019;34:571-578.
30. McClain RS, Terrell DR, Vesely SK, George JN. Plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: 2011 to 2014. *Transfusion.* 2014;54:3257-3259.
31. Aouad MT, Kanazi GE, Abdallah FW, et al. Femoral vein cannulation performed by residents: a comparison between ultrasound-guided and landmark technique in infants and children undergoing cardiac surgery. *Anesth Analg.* 2010;111:724-728.
32. Brass P, Hellmich M, Kolodziej L, Schick G, Smith AF. Ultrasound guidance versus anatomical landmarks for subclavian or femoral vein catheterization. *Cochrane Database Syst Rev.* 2015;1:CD011447.
33. Benhamou Y, Baudel JL, Wynckel A, et al. Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center. *Am J Hematol.* 2015;90:E127-E129.
34. Goel R, King KE, Takemoto CM, Ness PM, Tobian AA. Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012. *Transfusion.* 2016;56:1451-1458.
35. Swisher KK, Terrell DR, Vesely SK, Kremer Hovinga JA, Lammle B, George JN. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. *Transfusion.* 2009;49:873-887.
36. Cserti CM, Landaw S, Uhl L. Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura? *J Clin Apher.* 2007;22:21-25.
37. Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. *Blood.* 2010;115:1500-1511.
38. Westwood JP, Thomas M, Alwan F, et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. *Blood Adv.* 2017;1:1159-1166.
39. Jayabose S, Dunbar J, Nowicki TS, Tugal O, Ozkaynak MF, Sandoval C. Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child. *Pediatr Hematol Oncol.* 2011;28:167-172.
40. Ferrara F, Annunziata M, Pollio F, et al. Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura. *Ann Hematol.* 2002;81:7-10.
41. Ferrara F, Copia C, Annunziata M, et al. Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura. *Ann Hematol.* 1999;78:521-523.
42. Bobbio-Pallavicini E, Porta C, Centurioni R, et al. Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. The Italian Cooperative Group for TTP. *Eur J Haematol.* 1994;52:222-226.
43. Durand JM, Lefevre P, Kaplanski G, Telle H, Soubeyrand J. Vincristine for thrombotic thrombocytopenic purpura. *Lancet.* 1992;340:977-978.
44. Matsumoto M, Fujimura Y, Wada H, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. *Int J Hematol.* 2017;106:3-15.
45. Cataland SR, Kourlas PJ, Yang S, et al. Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. *Blood Adv.* 2017;1:2075-2082.
46. Yilmaz M, Eskazan AE, Unsal A, et al. Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature. *Transfusion.* 2013;53:1586-1593.
47. Nosari A, Redaelli R, Caimi TM, Mostarda G, Morra E. Cyclosporine therapy in refractory/relapsed patients with thrombotic thrombocytopenic purpura. *Am J Hematol.* 2009;84:313-314.
48. Cataland SR, Jin M, Lin S, et al. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. *Br J Haematol.* 2007;139:486-493.
49. Enami T, Suzuki T, Ito S, et al. Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine and corticosteroids in a patient with systemic lupus erythematosus and antibodies to ADAMTS13. *Intern Med.* 2007;46:1033-1037.
50. Cataland SR, Jin M, Ferketich AK, et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. *Br J Haematol.* 2007;136:146-149.

51. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. *Ann Intern Med.* 2003;138:105-108.
52. Beloncle F, Buffet M, Coindre JP, et al. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. *Transfusion.* 2012;52:2436-2444.
53. Lin TY, Chang CC, Chang CC, Yuan JY, Chen HH. Cyclophosphamide-rescued plasmapheresis-unresponsive secondary thrombotic thrombocytopenic purpura caused by Sjogren's syndrome. *Arch Med Sci.* 2012;8:934-938.
54. Kappers-Klunne MC, Wijermans P, Fijnheer R, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. *Br J Haematol.* 2005;130:768-776.
55. Thompson HW, McCarthy LJ. Thrombotic thrombocytopenic purpura. Potential benefit of splenectomy after plasma exchange. *Arch Intern Med.* 1983;143:2117-2119.
56. Hoffkes HG, Weber F, Uppenkamp M, et al. Recovery by splenectomy in patients with relapsed thrombotic thrombocytopenic purpura and treatment failure to plasma exchange. *Semin Thromb Hemost.* 1995;21:161-165.
57. Mant MJ, Turner AR, Bruce D, Ritchie C, Larratt LM. Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolonged plasma exchange dependency. *Am J Hematol.* 1999;62:56-57.
58. Dubois L, Gray DK. Case series: splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura? *Can J Surg.* 2010;53:349-355.
59. Moake JL, Rudy CK, Troll JH, et al. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. *Am J Hematol.* 1985;20:73-79.
60. Birgens H, Ernst P, Hansen MS. Thrombotic thrombocytopenic purpura: treatment with a combination of antiplatelet drugs. *Acta Med Scand.* 1979;205:437-439.
61. Myers TJ, Wakem CJ, Ball ED, Tremont SJ. Thrombotic thrombocytopenic purpura: combined treatment with plasmapheresis and antiplatelet agents. *Ann Intern Med.* 1980;92:149-155.
62. Breckenridge RL Jr, Solberg LA, Pineda AA, Pettitt RM, Dharkar DD. Treatment of thrombotic thrombocytopenic purpura with plasma exchange, antiplatelet agents, corticosteroid, and plasma infusion: Mayo Clinic experience. *J Clin Apher.* 1982;1:6-13.
63. del Zoppo GJ. Antiplatelet therapy in thrombotic thrombocytopenic purpura. *Semin Hematol.* 1987;24:130-139.
64. Revell P, Slater NG. Antiplatelet therapy in thrombotic thrombocytopenic purpura. *Lancet.* 1992;340:851-852.
65. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. *Haematologica.* 1997;82:429-435.
66. Chapin J, Weksler B, Magro C, Laurence J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. *Br J Haematol.* 2012;157:772-774.
67. Tsai E, Chapin J, Laurence JC, Tsai HM. Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. *Br J Haematol.* 2013;162:558-559.
68. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. *Drug Saf.* 1993;9:254-262.
69. Ryan ME, Webster ML, Statler JD. Adverse effects of intravenous immunoglobulin therapy. *Clin Pediatr (Phila).* 1996;35:23-31.
70. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. *Blood.* 2010;116:4060-4069.
71. Ferrari S, Palavra K, Gruber B, et al. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. *Haematologica.* 2014;99:779-787.
72. Ferrari B, Maino A, Lotta LA, et al. Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case-control study. *Orphanet J Rare Dis.* 2014;9:193.
73. McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. *J Thromb Haemost.* 2010;8:1201-1208.
74. Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. *Br J Haematol.* 2012;158:323-335.
75. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. *Blood.* 2011;117:1499-1506.
76. Sarode R, Bandarenko N, Brecher ME, et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. *J Clin Apher.* 2014;29:148-167.
77. Neave L, Scully M. Microangiopathic hemolytic anemia in pregnancy. *Transfus Med Rev.* 2018;32:230-236.
78. von Auer C, von Krogh A-S, Kremer Hovinga JA, Lämmle B. Current insights into thrombotic microangiopathies: thrombotic thrombocytopenic purpura and pregnancy. *Thromb Res.* 2015;135(Suppl 1):S30-S33.
79. Au WY, Chan KW, Lam CC, Young K. A post-menopausal woman with anuria and uterus bulk: the spectrum of estrogen-induced TTP/HUS. *Am J Hematol.* 2002;71:59-60.
80. Fraser JL, Millenson M, Malynn ER, Uhl L, Kruskall MS. Possible association between the Norplant contraceptive system and thrombotic thrombocytopenic purpura. *Obstet Gynecol.* 1996;87:860-863.
81. Hauglustaine D, Van Damme B, Vanrenterghem Y, Michielsen P. Recurrent hemolytic uremic syndrome during oral contraception. *Clin Nephrol.* 1981;15:148-153.
82. Hauglustaine D, Vanrenterghem Y, Michielsen OP, van Damme B. Oestrogen containing oral contraceptives, decreased prostacyclin production, and haemolytic uraemic syndrome. *Lancet.* 1981;1:328-329.
83. Liang R, Wong RW, Cheng IK. Thrombotic thrombocytopenic purpura and 17 beta-estradiol transdermal skin patch. *Am J Hematol.* 1996;52:334-335.
84. Stylianou K, Tsirakis G, Mantadakis E, et al. Refractory thrombotic thrombocytopenic purpura associated with oral contraceptives and factor V Leiden: a case report. *Cases J.* 2009;2:6611.
85. Dabak V, Kuriakose P, Raman S. Successful management of a Jehovah's Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange. *J Clin Apher.* 2007;22:330-332.
86. Martin MG, Whitlatch NL, Shah B, Arepally GM. Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness. *Am J Hematol.* 2007;82:679-681.
87. Walia SS, Walia MS, Walia HS. Thrombotic thrombocytopenic purpura treated with vincristine in a Jehovah's witness. *Asian J Transfus Sci.* 2011;5:180-181.
88. Chai W, Chaudhry A, Rabinowitz AP. Successful management of thrombotic thrombocytopenic purpura in a Jehovah's Witness without plasma exchange. *J Clin Apher.* 2015;30:46-49.
89. Malla M, Seetharam M. To treat or not to treat: a rare case of pseudo-thrombotic thrombocytopenic purpura in a Jehovah's Witness. *Transfusion.* 2016;56:160-163.
90. George JN, Sandler SA, Stankiewicz J. Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah's Witness experience. *Blood Adv.* 2017;1:2161-2165.

91. Baseri B, Vishwanathan S, Benasher D, Khazan M, Luhrs C, Tsai HM. Survival of a Jehovah's Witness with thrombotic thrombocytopenic purpura without using plasma: a case report and review of the literature. *J Clin Apher.* 2019;34:623-630.
92. Lim MY, Greenberg CS. Successful management of thrombotic thrombocytopenic purpura in a Jehovah's witness: an individualized approach with joint decision-making. *J Patient Exp.* 2020;7:8-11.

How to cite this article: Zheng XL, Vesely SK, Cataland SR, et al. Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. *J Thromb Haemost.* 2020;18:2503–2512. <https://doi.org/10.1111/jth.15009>